Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Non-Current Assets (2016 - 2026)

Iradimed has reported Non-Current Assets over the past 14 years, most recently at $28.0 million for Q1 2026.

  • Quarterly Non-Current Assets rose 5.17% to $28.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $114.4 million through Mar 2026, up 33.03% year-over-year, with the annual reading at $27.6 million for FY2025, 19.45% up from the prior year.
  • Non-Current Assets was $28.0 million for Q1 2026 at Iradimed, up from $27.6 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $29.8 million in Q3 2025 and troughed at $6.9 million in Q1 2022.
  • The 5-year median for Non-Current Assets is $16.2 million (2023), against an average of $18.1 million.
  • Year-over-year, Non-Current Assets dropped 1.39% in 2022 and then skyrocketed 112.21% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $8.0 million in 2022, then surged by 101.33% to $16.2 million in 2023, then soared by 42.89% to $23.1 million in 2024, then rose by 19.45% to $27.6 million in 2025, then grew by 1.43% to $28.0 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Non-Current Assets are $28.0 million (Q1 2026), $27.6 million (Q4 2025), and $29.8 million (Q3 2025).